What are the differences between Adderall XR (mixed amphetamine salts) and Vyvanse (lisdexamfetamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Key Differences Between Adderall XR and Vyvanse

Both Adderall XR and Vyvanse are amphetamine-based stimulants with similar efficacy for ADHD, but Vyvanse is a prodrug that requires conversion to active d-amphetamine in the blood, resulting in a smoother, longer duration of action (up to 13-14 hours) with potentially lower abuse liability compared to Adderall XR's immediate mixed amphetamine salts formulation.

Chemical Composition and Formulation

Adderall XR contains a 3:1 ratio mixture of four amphetamine salts 1:

  • Dextroamphetamine saccharate
  • Amphetamine aspartate monohydrate
  • Dextroamphetamine sulfate
  • Amphetamine sulfate

The capsule uses a double-pulsed bead delivery system that releases amphetamines in two waves, with peak plasma concentrations occurring around 7 hours post-dose 1.

Vyvanse (lisdexamfetamine) is fundamentally different—it's an inactive prodrug where d-amphetamine is covalently bonded to the amino acid l-lysine 2, 3. This chemical bond must be hydrolyzed in the blood before the drug becomes pharmacologically active 4, 5.

Pharmacokinetic Differences

The prodrug design of Vyvanse creates distinct pharmacokinetic advantages:

  • Onset: Vyvanse has a 0.6-hour longer lag time and reaches peak levels approximately 1 hour later than equivalent doses of d-amphetamine 6
  • Peak concentrations: Vyvanse produces lower maximum plasma concentrations (Cmax) with extended time to peak (Tmax) compared to immediate-release amphetamine 3
  • Duration: Vyvanse's therapeutic action extends to at least 13 hours in children and 14 hours in adults—longer than any other long-acting ADHD formulation 3
  • Variability: Vyvanse shows lower inter- and intra-individual variability in drug exposure compared to immediate-release amphetamine 3

Adderall XR reaches peak concentrations around 7 hours, with mean elimination half-lives of 10 hours (d-amphetamine) and 13 hours (l-amphetamine) in adults 1.

Clinical Efficacy

Both medications are highly effective first-line treatments for ADHD 7, 8. Stimulants as a class have an effect size of approximately 1.0 for ADHD treatment 7.

In direct comparison studies, Vyvanse demonstrated significant improvements in ADHD symptoms versus placebo, with efficacy comparable to mixed amphetamine salts extended-release 2. A meta-analysis found Vyvanse had the largest effect size (SMD -0.89) compared to mixed amphetamine salts (SMD -0.64) and methylphenidate (SMD -0.50) 9.

Guidelines recommend that if methylphenidate fails at adequate doses, lisdexamfetamine should be the preferred next option over non-stimulants 8.

Abuse Liability Considerations

This is a critical differentiator in clinical practice:

Vyvanse's prodrug design theoretically reduces oral abuse potential because:

  • The drug requires enzymatic conversion in blood to become active 3, 4
  • Drug-liking scores are lower than equivalent doses of immediate-release d-amphetamine 3
  • The reduced euphorigenic potential is associated with its smoother pharmacokinetic profile 3

However, one controlled study found that when comparing equimolar doses, no differences in peak ratings of abuse-related subjective effects (drug liking, drug high, stimulation) were observed between lisdexamfetamine and d-amphetamine 6. The study concluded that lisdexamfetamine is "likely associated with a similar risk of oral abuse as d-amphetamine" 6.

Both medications are Schedule II controlled substances 1 and carry significant abuse and dependence risks with chronic use.

Practical Clinical Considerations

Duration of coverage: Vyvanse's 13-14 hour duration may provide better all-day symptom control, particularly beneficial for patients needing evening coverage for homework or work responsibilities 3.

Dosing convenience: Both are once-daily formulations, improving adherence compared to twice-daily regimens 8. Once-daily dosing should generally be preferred to enhance medication adherence 8.

Individual response variability: Approximately 40% of patients respond to both methylphenidate and amphetamine, while 40% respond to only one 7. This idiosyncratic response pattern means some patients may respond better to one formulation over the other.

Side effect profiles: Both medications produce similar adverse events including decreased appetite, headache, stomach pain, and cardiovascular effects 8. The safety profiles are comparable 2.

Common Pitfalls to Avoid

  • Don't assume Vyvanse is "safer" regarding abuse—while the prodrug design may reduce certain abuse routes, oral abuse potential remains significant 6
  • Don't overlook that both medications require careful cardiovascular monitoring and assessment for psychiatric comorbidities
  • Don't forget that approximately 40% of patients may not respond to amphetamine-based medications and may require methylphenidate instead 7
  • Remember that the ADHD subtype does not predict response to specific agents 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.